JPMorgan raised the firm’s price target on Imax (IMAX) to $31 from $28 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the cinema group. The firm reduced its Q3 and 2025 box office outlook but has increased conviction in 2026 estimates after taking an early look at the first half release slate.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAX:
- IMAX: Strong Buy Rating Backed by Exceptional Performance and Growth Prospects
- IMAX’s Strong Market Position and Growth Potential Drive Buy Rating
- Taylor Swift plans return to movie theaters, Hollywood Reporter says
- Imax price target raised to $37 from $32 at Barrington
- Imax sets new record for local language box office